NEW YORK – BostonGene and Sarah Cannon Research Institute (SCRI) on Tuesday said they will collaborate to integrate molecular testing and informatics platforms into Phase I clinical studies at SCRI trial sites.
Waltham, Massachusetts-based BostonGene will contribute its Tumor Portrait tests to the partnership to generate metrics such as HLA typing, microenvironment profiles, RNA expression levels, gene alterations, trial enrollment, treatment outcomes, and therapy duration. BostonGene and SCRI aim to explore the effect of pre-screening patients by HLA genotype for clinical trials.
"This collaboration will enable us to personalize cancer treatment more effectively and expedite biomarker discovery and validation, ultimately shifting the standard of care and improving patient outcomes," BostonGene Chief Medical Officer Nathan Fowler said in a statement.
BostonGene has recently inked numerous similar partnerships with organizations such as Mount Sinai, Takeda, and the Sylvester Comprehensive Cancer Center.